Peptide Profiles
What Is Retatrutide? The Triple Agonist Peptide Explained
Retatrutide (LY3437943) is one peptide that activates GIP, GLP-1 and glucagon receptors. Its pharmacology, half-life and trial results.
Published work on energy balance, glucose handling, lipid metabolism and the receptors involved. Each result is reported with the species and model it came from, because a rodent metabolic result and a human pharmacokinetic result are not interchangeable evidence.
Peptide Profiles
Retatrutide (LY3437943) is one peptide that activates GIP, GLP-1 and glucagon receptors. Its pharmacology, half-life and trial results.
Research Reviews
Retatrutide's half-life in humans is about 6 days in a phase 1b trial. How it was measured, why it is so long, and what it means for stability.
Comparisons
Semaglutide is a selective GLP-1 receptor agonist; retatrutide activates GIP, GLP-1 and glucagon receptors. Structure, half-life and trial endpoints compared.
Comparisons
Retatrutide adds glucagon receptor activity to tirzepatide's GIP/GLP-1 agonism. Receptors, half-life, status and trial endpoints compared.
Peptide Profiles
AOD-9604 is a 16-residue analogue of hGH 177-191 with an added tyrosine. Its structure, rodent lipid-metabolism studies and detection methods.
Peptide Profiles
Cagrilintide is a lipidated, long-acting amylin analogue acting on amylin and calcitonin receptors. Its design, mechanism and phase 2 data.
Lab Handling
Reconstituting lyophilized retatrutide for research: solvent choice for a lipidated peptide, concentration tables for 5–60 mg vials, mixing and storage.
Lab Handling
Reconstituting research tirzepatide: stock solutions, mg/mL to micromolar conversion at 4813.5 Da, dilution for cell assays, low-binding plastics and storage.
Peptide Profiles
Yes: GLP-1 is a ~30 amino acid peptide hormone from proglucagon. How native GLP-1 differs from long-acting analogues and co-agonist peptides.
Peptide Profiles
Tirzepatide is a 39-residue lipidated peptide acting on GIP and GLP-1 receptors. Its structure, discovery, pharmacokinetics and key trial data.